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1. Introduction 15 
Structures in biology display various morphologies. Morphological characteristics, such as 16 
size and shape, are determining factors in the function of a host of nano- and microsized biomaterials. 17 
Intrigued and inspired by the intricacy of natural architectures, researchers (from various backgrounds) 18 
seek to develop artificial counterparts in order to replicate and thereby harness their function for 19 
diverse applications, from drug delivery to electronic sensing. In particular, well-defined nanoparticles 20 
with various morphologies are a great interest for biomedical research.[1] To this end, researchers are 21 
in search of a diverse molecular toolbox from which a broad range of nanoscopic architectures can be 22 
constructed with discrete properties dictated by the physicochemical attributes of their respective 23 
building blocks. Such nanoengineering is inspired by the plethora of intermolecular driving forces 24 
associated with self-assembled biological structures, which can be harnessed by the generation of 25 
synthetic, supra-molecular architectures that possess the requisite chemical versatility to facilitate 26 
application in biomedical research. The impact of morphologically discrete nanoparticles upon the 27 
development of nanomedicine is an important topic, gaining increasing attention for its potential to 28 
provide a new avenue for the development of future therapeutic technologies. Scheme 1 provides an 29 
overview of the adaptive morphologies of nanoparticles based on block copolymers in anticancer 30 
nanomedicine. 31 
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 1 
Scheme 1. Overview of adaptive morphologies in anticancer nanomedicines. 2 
 3 
Nanomedicine focuses upon the use of nanoparticles between 1-100 nm in diameter and of 4 
broad chemical compositions to be used towards various applications in the life sciences (Figure 1). 5 
During the last decade, the field of nanomedicine has witnessed rapid growth, with promising results 6 
that indicate great potential to address challenging diseases such as cancer.  7 
Although a large library of molecular therapeutics has been designed and deployed against 8 
cancer, due to the unsurpassable barriers of physicochemical limitations (such as low solubility and 9 
instability) or poor specificity such drugs encounter to their implementation, cancer continues to be 10 
one of the deadliest diseases affecting human health today. Conventional anticancer treatments, such 11 
as chemo- and radiotherapy, cause damage to both healthy and diseased tissue, significantly 12 
decreasing the survival rate while requiring medical reexamination. In contrast, Doxil®, a pioneering 13 
example of an effective nanomedical formulation, is a liposomal system utilizing the ‘stealth’ behavior 14 
of a poly(ethylene glycol)(PEG)-ylated surface along with high drug-loading capacity that was FDA-15 
approved and brought to market in 1995.[2] More recently, Abraxane®, based on albumin-stabilized 16 
nanoparticles, has also come to market for breast cancer therapy. Although these products have 17 
spearheaded the presence of nanomedicine in the market, research continues towards the generation of 18 
functional nanotechnologies with greater efficacy in vivo through the optimization of morphological 19 
characteristics. 20 
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 1 
Figure 1. Schematic demonstrating the various nanoplatforms currently being studied for their 2 
therapeutic applications. Reprinted with permission from reference.[3] 3 
 4 
One of the most well-established, beneficial properties of nanomedical formulations is their 5 
stealth-like character, which prevents clearance by renal filtration and the mononuclear phagocyte 6 
system (MPS) associated with the process of opsonization. Such processes occur shortly after 7 
nanoparticles enter the bloodstream, hindering their therapeutic efficacy and limiting their circulation 8 
time.[4] Stealth characteristics of nanoparticles can be introduced through a process called PEGylation, 9 
where poly(ethylene glycol) (PEG) is used to create a hydrophilic, low protein binding surface to 10 
reduce opsonization and thereby evade the MPS.[5] For this reason, the use of PEG as the hydrophilic 11 
block in the self-assembly of amphiphilic components is a common practice. Although the engineering 12 
of complex nanoarchitectures is not a new field, it has undergone a fundamental shift in recent years. 13 
With increasing attention being given to morphological features on the nanoscale, it is increasingly 14 
recognized that changes in the physicochemical attributes of a nanoparticle can have significant 15 
consequences for their behavior in a biological setting. In terms of particle size, relatively large 16 
nanotherapeutics are less effective at treating solid tumors due to their preferential association with 17 
peripheral cells after extravasation from adjacent blood vessels, limiting penetration and 18 
compromising efficacy.[6] Such limited tumor penetration in nanomedicine has been wildly recognized 19 
as the main hindrance in the treatment of solid tumors. Beyond the effect of particle size, which is a 20 
well-established factor, another key factor that has emerged is shape.[7] Despite their large size, red 21 
blood cells (RBCs) are able to smoothly navigate through the spleen slits because of their unique 22 
biconcave, discoidal shape and mechanical flexibility. Such a key morphological feature can be 23 
exploited in the design of nanoparticles in order to mimic the performance of RBCs, which might 24 
allow for longer distribution and decreased renal filtration.[8] Until now, there have been very few 25 
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nanoparticles with novel structures that could meet the requirements for particle size while effectively 1 
achieving both enhanced tumor accumulation/retention and deeper penetration.[6] Therefore, rationally 2 
engineering the morphological properties of nanoparticles provides a promising avenue of 3 
development to address key limitations of nanomedical technology (Figure 2). 4 
 5 
 6 
Figure 2. Intelligent particle design determines the distribution of nanoparticles in the bloodstream 7 
and their interaction with cells is tailored by their contact surface resulting from morphological 8 
features. Reprinted with permission.[7] 9 
 10 
Successful fabrication of nanoparticles with nanomedical applications relies heavily on their 11 
ability to overcome various biological barriers. With this in mind, researchers now seek to engineer 12 
adaptive nanoparticles that are able to explore new frontiers for the development of increasingly 13 
effective nanomedical formulations. For example, the biological (immunological) response to size-14 
controlled particles is well studied. Conventional stealth nanomedical formulations (< 400 nm) are 15 
recognized to accumulate in solid tumor regions but are poor at penetrating the dense collagen matrix, 16 
which greatly limits efficacy. Conversely, smaller nanomedicines (< 30 nm) demonstrate far more 17 
effective tumor penetration, potentially improving treatment because of a reduced diffusional 18 
hindrance. However, such particles suffer from rapid clearance by renal filtration and inferior 19 
circulation half-life time with inefficient tumor accumulation/retention because of their ability to re-20 
enter the bloodstream.[4] Currently, research is focused on exploiting the enhanced permeation and 21 
retention (EPR) effect as a method of passively diffusing particles through the (leaky) endothelial 22 
vascular wall of tumors.[9] However, the EPR effect only occurs in fast growing tumors, severely 23 
limiting its application as a general targeting mechanism. Additionally, only a small amount of 24 
nanoparticles eventually reach the tumor tissue, fueling discussion as to whether exploitation of the 25 
EPR effect is a viable strategy for nanomedicine.[10] As opposed to passive targeting mechanisms, 26 
active targeting, using surface-bound antibodies, ligands or peptides, can be employed to selectively 27 
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direct nanoparticles towards specific tissues. Although this strategy has been adopted in a number of 1 
studies, active targeting is limited by the need for nanoparticles to be in close proximity to the targeted 2 
tissue.[11] Although targeting might increase selectivity and cell uptake in vitro, effective targeting in 3 
vivo is minimal. It is necessary to consider the broader role of particle morphology when translating 4 
nanoparticles in vivo; for example, active targeting motifs can increase properties such as particle size, 5 
significantly changing the distribution behavior and cellular uptake.[12] With this in mind, adapting the 6 
morphology of nanoparticles to synergistically enhance efficacy is an important strategy. For example, 7 
elongated particles show deeper tumor tissue penetration and interact with a larger volume fraction of 8 
the surrounding vasculature than that of spherical particles.[13] With shape and size being such 9 
essential factors that influence targeting properties, the versatility of polymeric vesicles can be 10 
effectively utilized to engineer materials that can be adaptive to their direct environment. 11 
Adaptive nanosystems, which display unique morphological features in order to 12 
synergistically enhance performance in vivo, can be effectively engineered utilizing the self-assembly 13 
of block copolymers (BCPs). The capacity of synthetic BCP vesicles (‘polymersomes’) to embody a 14 
number of key properties such as compartmentalization and discretization have been established.[14–16] 15 
BCP membranes display the same amphiphilic character as lipids but are more stable and chemically 16 
versatile.[17] Self-assembly of BCP nanosystems has been studied extensively to unravel their 17 
dynamics, with polymer geometry and packing determining particle morphology (e.g., lamellar, 18 
micellar or vesicular; Figure 3).[18] Although micellar systems show great promise as drug delivery 19 
platforms, their relative instability compared to polymeric vesicles is disadvantageous for long 20 
circulation and targeting studies. The chemical versatility of polymersomes allows the engineering of 21 
various morphologies with control over chemical composition, size, shape, surface chemistry and 22 
functionality being of significance when their performance in biological context is to be considered 23 
and evaluated.  24 
 25 
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 1 
Figure 3. Schematic demonstrating the bottom-up design of the controlled self-assembly of block 2 
copolymers into nanoparticles, where intelligent polymer design (a) and self-assembly conditions (b) 3 
can influence resulting particle morphology (c). Reprinted with permission.[1] 4 
 5 
2. Block copolymer particles as platforms for therapeutic and smart drug delivery applications 6 
2.1 Polymeric nanoparticles as therapeutic platforms 7 
There is a wide range of copolymers and fabrication methodologies that have been presented 8 
in the literature, many of which have properties that have potential for nanomedical applications.[1] Of 9 
particular interest is the ability to adapt spherical polymersomes into other morphologies (such as 10 
tubes, discs and stomatocytes) using shape transformation methodologies, which greatly enhances the 11 
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versatility and the applicability. Although there has been substantial progress towards the generation 1 
of polymersomes for biological applications, this is usually accomplished via the self-assembly of 2 
nonbiocompatible/degradable components comprising building blocks such as polystyrene (PS) and 3 
poly(dimethyl siloxane) (PDMS).[19,20] To further develop the utility of copolymers, an important 4 
consideration is biocompatibility, which can be imparted through the use of biodegradable subunits 5 
such as polyesters and polycarbonates. With this in mind, biodegradable polymers, such as poly(ε-6 
caprolactone), polylactide and poly(trimethylene carbonate), have been presented as excellent 7 
candidates for developing nanostructures that are inherently biocompatible; however, achieving 8 
control over the self-assembly of such materials remains a challenge. Fine-tuning the self-assembly of 9 
particular copolymers can be accomplished through systematically engineering both physical and 10 
chemical aspects. Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) has been 11 
extensively studied and is FDA-approved for biological applications. PCL undergoes degradation by 12 
means of enzymatic and nonenzymatic hydrolysis into nontoxic products and has been shown to 13 
undergo self-assembly using the biocompatible direct hydration method, which has potential for the 14 
encapsulation of active materials.[21] Investment in this kind of nanoengineering can fuel the 15 
development of functional nanosystems by providing insight and expertise in the fabrication of 16 
copolymeric nanoparticles with well-defined morphological characteristics, which is of great 17 
significance to a broad scientific audience. 18 
Another important feature of polymersomes that has an impact over their implementation in 19 
biomedical applications regards the permeability of their membrane. A number of different approaches 20 
have been described to provide control over the permeability of copolymeric bilayers. For example, 21 
polyionic complex-based polymersomes (PICsomes) have been shown to be permeable to small 22 
compounds due to the loose packing of their membranes.[22,23] Engineering the composition of the 23 
polymersomal membrane can be used to introduce hydrolysis, pH- or UV-sensitive moieties that can 24 
induce stimulus-responsiveness permeability.[24,18,19] The porosity of polymersomes has also been 25 
established by the insertion of channel proteins, such as OmpF or Aquaporin Z, creating channels for 26 
selective molecular transportation.[25] Recently, polymersomal nanoreactors have been developed that 27 
encapsulate enzymatic cargo, which are capable of regulating cascade reactions and can be applied in 28 
cellular therapies as a kind of ‘synthetic organelle’. These synthetic organelles are interesting 29 
candidates as to not only gain a deeper understanding of the intracellular processes but also to enhance 30 
the activity of existing organelles and actively produce drugs.[25]  31 
2.2 Adaptive polymeric nanoparticles for smart drug delivery 32 
Having established the design principles that underpin polymersome fabrication and control 33 
over morphology,[26,18] it is also pertinent to consider how we might induce more dynamic adaptability 34 
into such systems. Such a paradigm shift from exploring the fundamental principles of polymer self-35 
assembly towards the design of dynamic systems has significant potential in the generation of smart 36 
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drug delivery technologies. Smart polymeric technologies are capable of undergoing some kind of 1 
morphological switch in response to a change in the local environment as a consequence of a chemical 2 
or physical stimulus. For example, stimulus-responsive polymersomes have been designed to respond 3 
to certain biological environments in order to allow site-specific, ‘on-demand’ release of cargo (Figure 4 
4).[27]  5 
 6 
Figure 4. Schematic showing the responsive behavior of a redox-responsive nanoparticle influenced 7 
by the concentration of glutathione (GSH) corresponding to the environment inside and outside of 8 
cells. Reprinted with permission.[28] 9 
 10 
Size switchable nanoparticles (SSNs) have been developed to adjust their size when triggered 11 
by an environmental (internal) or external trigger. [29–31] Chemically, SSNs respond to changes in local 12 
environment, for example, in peripheral tumor tissues through bond cleavage, protonation, or 13 
conformational changes that effect major changes in the overall structure. For application in treatment 14 
of solid tumors, SSNs are engineered to adapt their hydrophilic/hydrophobic properties, 15 
association/disassociation interactions, or alter their surface charge in response to increased local 16 
acidity (pH 6.5–6.8), which enables them to preferably embed and thereby improve therapeutic 17 
outcomes. In comparison with conventional stealth nanoparticles, SSNs can achieve adaptive behavior 18 
so that a morphological transformation occurs after accumulation/retention in the tumor region, 19 
resulting in the generation of smaller nanoparticles (< 50 nm).[32] The resultant smaller nanoparticles 20 
can undergo deeper tumor penetration and efficient nuclear uptake, whereas the original larger 21 
particles display a prolonged circulation time, all of which is integrated into a single nanoplatform. 22 
Alternative triggers, such as enzyme-, pH- and reduction/oxidation-responsive materials have also 23 
been fabricated to induce cargo release around tumor tissue.[33] External stimuli, such as temperature, 24 
light or ultrasound are additional intriguing features for intelligent polymer drug delivery platforms 25 
with increased efficacy and efficiency.[34] Wang et al developed ultra-pH-sensitive cluster nanobombs 26 
(SCNs) by rational self-assembly of poly(ethylene glycol)-b-poly(2-azepane ethyl methacrylate)-27 
modified PAMAM dendrimers (PEG-b-PAEMA-PAMAM/Pt), in which a platinum prodrug was 28 
conjugated.[29] After accumulation/retention in the acidic tumor region, the PAEMA block became 29 
hydrophilic due to its ultrasensitive pH responsiveness and rapid protonation, resulting in cluster 30 
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disassembly and instantaneous disintegration of the superstructure into small nanoparticles. Upon 1 
disassembly, covalently conjugated Pt-prodrug on the dendrimer was specifically reduced by 2 
intracellular abundant GSH to great therapeutic effect. Matrix metalloproteinases (MMPs), especially 3 
MMP2, are recognized to be involved and overexpressed in many stages of human cancers.[35] 4 
Nanoparticle delivery systems bearing MMP-sensitive moieties allow specific stimulus responsiveness 5 
in the tumor region. A sophisticated design of size changeable nanocarriers based on the abnormal 6 
expression of MMP-2 in the tumor region was recognized as a promising approach for dual-targeted 7 
delivery to solid tumors. In a recent study, an SCN with tunable size was prepared by Hu et al, which 8 
was formed by covalent conjugation of hypoxic microenvironment targeting tungsten oxide 9 
nanoparticles (~5 nm) with a matrix MMP-2 cleavable peptide (Pro-Leu-Gly-Val-Arg-Gly).[35] Upon 10 
entering into the MMP-2 overexpressed tumor region, bond cleavage resulted in detonation of the 11 
nanobomb, effectively releasing tungsten oxide nanoparticles to achieve deep tumor penetration. A 12 
switchable spiropyran-based nanoparticle that responds to an exogenous trigger (UV light) has been 13 
described by Kohane et al,[36] which upon UV light irradiation underwent a volume decrease, 14 
enhancing tissue penetration and drug release. Although nanoparticle characteristics such as size, 15 
chemical composition and membrane permeability are critical decisive factors in their performance in 16 
drug delivery applications, the effect of shape remains elusive. However, one can envision that the 17 
morphological characteristics of nanoparticles might have an influence on their capacity for drug 18 
transportation and release. It is important to explore the behavior of a wide range of shapes of 19 
nanoparticles in order to understand and develop system versatility and utility. 20 
Micro or nanoreactors are versatile systems that allow for catalytic or cascade reactions to take 21 
place in a controlled environment such as the inner compartment of polymeric vesicles. Driven by 22 
membrane permeability, nanoreactors can process active compounds using catalysts sequestered inside 23 
the vesicle, releasing products in the vicinity of the particle.[37,38] Such compartmentalized systems 24 
reduce the diluting effect that occurs when free active compounds are distributed in the body and 25 
prevents premature chemical degradation or processing by the immune system. Inspired by viruses, 26 
several types of nanoreactors have been developed. Responsive nanoreactors are highly interesting 27 
candidates as they rely on site-specific activation of the catalytic properties of the system. The in situ 28 
activation of drugs, or prodrugs, can occur by deactivating the active compound by, for example, 29 
immobilization on the polymer shell.[39] In a specific example, the anticancer drug camptothecin (CPT) 30 
was immobilized in the membrane of a pH-sensitive polymersome (Figure 5) via an oxidation-31 
sensitive linkage. Glucose oxidase, a highly efficient catalyst generating H2O2 through oxidation of 32 
glucose and often studied as an oxidation therapeutic, was encapsulated in the vesicle. By lowering the 33 
pH, the membrane permeability was increased allowing glucose to be converted by the enzyme into 34 
gluconolactone and H2O2. The production of the latter increased oxidative stress in tumors, inducing 35 
cell death, and additionally released the CPT into the environment.  36 
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 1 
Figure 5. Prodrug-based nanoreactor displaying increased permeability in low tumor environmental 2 
pH, thus activating the release of CPT and the formation of peroxide. Reprinted with permission.[39] 3 
 4 
Although our ability of decorating structures and creating certain functions to mimic the 5 
natural environment has improved greatly over the years, it also has led to the development of 6 
multifunctional nanoparticles that tend to suffer from over-complexity. Each addition influences not 7 
only the materials’ physicochemical properties but also, and more importantly, their biological 8 
behavior. Although this over-complexation might aid in the understanding and development of 9 
complex materials such as artificial cells and organelles, it is vital for the progress of this research 10 
field to maintain focus on the subject and, described by ‘less-is-more’, steer clear from researching 11 
materials that in the end do not benefit the purpose. Additionally, as functionalization on a high 12 
number of particles, as is usually the case, causes a statistical disparity in added functionality to 13 
particles, more additions lead to larger significant difference between the particles. This broad 14 
deviation in true functionality might result in unwanted or unrealistic effects when studying the 15 
biological response of these particles. The morphology of nanoparticles, including size and shape, is 16 
an interesting factor to study how different particles migrate through the body and penetrate tissue and 17 
cells. Demonstrated in multiple studies, the morphology has such a profound effect on these subjects 18 
that the addition of multiple functionalities might prove redundant. 19 
3. Controlling the morphology of polymeric nanoparticles 20 
Pioneering research was performed by the Mitragotri group on the fabrication of nanoparticles 21 
with different morphologies.[40,41] This was achieved using a polymer substrate which was 22 
subsequently subjected to stretching, yielding elongated particulates of different sizes and aspect 23 
ratios. The effect of particle morphology on uptake in macrophages or tumor cells along with 24 
biodistribution was studied. Elongated or wormlike structures were found to inhibit phagocytosis by 25 
macrophages due to their high aspect ratio and high flexibility.[42] On average, nanoparticles with 26 
higher aspect ratios inhibited uptake more extensively compared to spherical particles. Aside from 27 
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elongated structures, several, more exotic, morphologies were studied regarding cell uptake, 1 
internalization and biodistribution. The DeSimone group developed the PRINT technique, in which a 2 
liquid polymer precursor can be molded and cured to form any desired shape, finding that particle 3 
design influences cellular integration pathways and cell uptake.[43,44] Although present methods 4 
provide sturdy and monodisperse particles, their solid nature and large size introduce limitations in 5 
drug encapsulation and subsequent utilization in nanomedicine.[45] Using a different approach, the 6 
Lecommandoux group investigated the effect of hypo- and hypertonic shock upon the morphology of 7 
polymersomes and observed the formation of nested vesicles and stomatocytes under hypertonic 8 
conditions.[20] Over the past decade, the van Hest group has been developing methodologies to control 9 
shape transformations of polymersomes, with effective methodologies developed for both PEG-10 
poly(styrene) (PEG-PS) and PEG-poly(D,L-lactide) (PDLLA).[47,48] Significantly, shape 11 
transformations of spherical PEG-PDLLA polymersomes into both oblate and prolate structures can be 12 
induced by an osmotic pressure applied on the membrane during low-temperature dialysis. Physical 13 
factors such as polymer composition and membrane thickness were found to influence the subsequent 14 
direction of shape transformation that may additionally influence membrane flexibility and stiffness. 15 
Oblate structures, also named stomatocytes, consist of a stomach which has an opening connecting the 16 
outer environment to the inner lumen. Such stomatocytes have been utilized in the fabrication of 17 
nanomotors towards biomedical applications.[48,49] Driven by platinum nanoparticles, stomatocyte 18 
nanomotors were a significant development in the generation of autonomous, chemotactic 19 
nanotechnologies with propulsion generated by degradation of H2O2 into oxygen.[50] Abdelmohsen et 20 
al demonstrated that enzymatic cascade reactions inside stomatocytes could be utilized as a form of 21 
biocompatible propulsion, being induced by the presence of both catalase and glucose oxidase (Figure 22 
6).[51] Catalase is capable of efficiently decomposing hydrogen peroxide into water and oxygen. When 23 
combined with glucose oxidase, glucose can be decomposed into hydrogen peroxide, which is then 24 
decomposed by catalase into oxygen nanobubbles. The generation of oxygen results drives the thrust 25 
of these stomatocytes. 26 
 27 
Figure 6. Enzyme-loaded stomatocytes generate oxygen by fueling catalase with glucose via a 28 
cascade reaction yielding self-propelling particles (A). The concentration glucose influences the 29 
particles’ speed (B). Reprinted with permission from reference.[52] 30 
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Incorporating active macromolecules into stomatosomal compartments is an interesting basis 1 
for their implementation for nanomedical applications such as drug delivery and immunology. 2 
However, the nondegradable nature of PS-based nanocompartments, severely limits their applications 3 
in biological settings. To this end, van Hest et al explored the utility of biodegradable copolymers for 4 
self-assembly to unravel their potential in nanomedical research (Figure 7).[47] With fine tuning of the 5 
self-assembly through systematic engineering of the physical and chemical process, elongated 6 
nanotubes and bowl-shaped stomatocytes were prepared from biodegradable subunits. The ability to 7 
design such structures from biodegradable components holds great potential for nanomedical 8 
applications.[53]  9 
 10 
Figure 7. Schematic describing the influence of the spontaneous curvature on the resulting 11 
morphology of osmotically induced shape-transformation on PEG-PDLLA polymersomes. Reprinted 12 
with permission.[47] 13 
 14 
4. Influence of shapes of nanoparticles on their anticancer effects in vitro 15 
As has been alluded to, the morphology of nanoparticles plays a large role when their 16 
interactions with cells and organs have to be considered. The ability to engineer polymeric 17 
nanoparticles with such interesting morphological characteristics and the capacity to be adapted for, or 18 
in response to, specific biological environments is now being harnessed for proof-of-concept 19 
biochemical testing both in vitro and in vivo. Invaluable studies were performed to compare the 20 
antitumor efficacy of nonspherical nanoparticles to their spherical counterparts in vitro and in vivo. A 21 
delicate interplay of factors concerning cellular uptake mechanisms, distribution, and tumor 22 
accumulation leads to the notion that the morphology of nanoparticles seemingly affects the 23 
biodistribution and the reduction of tumor volume. Dendrimeric structures combined with docetaxel 24 
were able to form either nanospheres or nanosheets by varying their molecular weight ratios. The 25 
antitumor efficacy in vivo was almost 2-fold better for the sheets than that of the spherical particles.[54] 26 
Discoidal porous silica nanoparticles demonstrated a five-fold increased accumulation in breast tumor 27 
mass.[55] Formation of PLGA nanoparticles demonstrating porous matrix and rough surface showed 28 
increased in vivo antitumor efficacy compared to nonporous, smooth PLGA particles, owing to their 29 
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high drug loading and high dispersion in tumor sites.[56] Until now, systematic studies have only been 1 
performed with elongated particles, in particular rod-like filomicelles, which will therefore be the main 2 
topic of discussion in the next sections. 3 
4.1 Cellular internalization of shaped micelles 4 
A typical approach to improve or induce cellular uptake of nanoparticles is to trigger the 5 
energy-dependent cell endocytosis mechanisms to undergo clarthrin- and caveolae-mediated 6 
endocytosis or micropinocytosis.[57] The mechanism of endocytosis is not only dependent on the nature 7 
of the targeted receptors and cell types but also on the particles’ physicochemical properties, such as 8 
size, surface chemistry, shape, and elasticity.[58–61] For the effect of morphology, it seemed that the 9 
local geometry, local curvature and mean curvature, of particles in contact with the cell affect the 10 
endocytosis efficiency.[62,63] Park et al fabricated keyboard character shapes and found that those with 11 
sharp features and higher aspect ratios (such as letter I, number 1, and arrow key) adhere more to the 12 
LnCAP prostate cancer cells and are internalized within 75 min. In contrast, shapes without sharp 13 
features, such as the letters D, G, O, and the number 0, were unable to attach or penetrate the cells.[64] 14 
The sharper objects seemed to unable the cells to recruit more actin filaments and attach and engulf the 15 
objects than those without sharp features. Ma reported that PEGylated graphene nanosheets could 16 
hardly be internalized, and more likely adsorb onto or partially insert into the cell membrane in face-17 
on/edge-on configurations.[65] Cylindrical polystyrene nanoparticles showed increased specificity of 18 
endothelial targeting compared to the spheres,[66] due to the balance of polyvalent interactions that 19 
favor adhesion and entropic losses as well as shear-induced detachment that reduce binding.  20 
For cylindrical particles, the aspect ratio showed great influence on the cell uptake behavior. 21 
Shapes with higher aspect ratios could be internalized by the cells faster than those of lower aspect 22 
ratios,[44] which might be due to their larger surface area that enhances the interaction with cell 23 
membranes. However, contradictory results have been reported. For other nanoparticles, high aspect 24 
ratios seemed to reduce internalization and prolong the blood circulation time and cell targeting 25 
capability.[66,67] For nanoparticles shaped as the keyboard character solid arrow, internalization 26 
involved first the attachment of the arrowhead part to the cell membrane for 50 min and cell 27 
membrane extension to induce internalization, followed by reorganization of actin to allow uptake of 28 
the remainder of the nanoparticle. The internalization happened within approximately 80 min and was 29 
completed after 2-3 h.[64] Stenzel et al reported that fructose-based cylindrical micelles with smaller 30 
aspect ratios were internalized by cells significantly more and faster than medium and long ones by 31 
breast cancer cells in 2D and 3D tumor spheroids models.[68] Most likely, long rods need to overcome 32 
a higher membrane bending energy barrier during endocytosis than short ones. Discher et al 33 
investigated systematically the endocytosis of filomicelles of PEG-PCL and PEG-poly(butadiene) 34 
(PEG-PBD) by phagocytic cells and nonphagocytic cells. It was found that shorter micelles were taken 35 
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up more than the long ones (3 µm) by phagocytic cells and multisite attachment between cells and 1 
filomicelles was observed (Figure 8A).[67] Under flow conditions, short filomicelles adhered to and 2 
were taken up significantly more by phagocytes owing to the stronger interaction with the cells and a 3 
lesser effect of the flow; shear forces tend to minimize the interactions of long filomicelles with 4 
phagocytes, as they flow-align them and pull them off phagocytes as they come into contact. 5 
Fragments of long filomicelles might break off faster than the shorter ones and only micelles smaller 6 
than 2.5 µm were taken up significantly by the phagocytes (Figure 8B), while nonphagocytic epithelial 7 
cells rapidly pinocytosed filomicelles and trafficked them actively to the perinuclear region. The 8 
pinocytosis process reduced the length of the filomicelles and left only 2.5-µm long micelles in the 9 
culture (Figure 8C). 10 
15 
 
(A) (B)
(C)
(E)(D)
 1 
Figure 8. In vitro and in vivo experiments with filomicelles. (A) Fluorescence intensity of 2 
macrophages incubated with fluorescent filomicelles of varying length for 24 h in static cultures. (B) 3 
In an in vitro flow chamber with immobilized phagocytes, long filomicelles (right) flowed past the 4 
cells and left a fragment. Smaller micelles were captured (left). Scale bars represent 5 µm. (C) Uptake 5 
of filomicelles by epithelial cells. (D) Circulation half-life of filomicelles as a function of micelle 6 
length. (E) Shrinkage of A549 tumor xenografts in nude mice which were injected i.v. with PTX 7 
loaded filomicelles containing different PTX doses (n = 4). Reprinted with permission.[67] 8 
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For cylindrical particles, anchoring active targeting ligands not only changes the surface 1 
properties but also potentially changes the way of cell entry.[69] Based on the long circulation and 2 
minimal accumulation of filomicelles in the rat lung,[70] the development of specific targeting 3 
cylindrical particles to specific sites can eventually lead to effective drug delivery.[66] Discher et al 4 
designed antibody coupled filomicelles with tailored receptor ligands of high and low affinity to 5 
manipulate the specific targeting to endothelial walls.[71] The biotinylated wormlike micelles were 6 
internalized by receptor-mediated endocytosis either through packaging of the micelle or 7 
fragmentation.[72] The fructose moieties on the cylindrical micelle surfaces promoted their 8 
internalization via receptor-mediated endocytosis owing to the excellent affinity of fructose to GLUT5 9 
receptors that are overexpressed on breast cancer cells.[68]  10 
Moreover, the chemistry of the materials influences the cell uptake as well. PEG-PCL 11 
modified with aromatic moieties in the hydrophobic domain, PEG-poly(alpha-benzyl carboxylate ε-12 
caprolactone) (PEG-PBCL), assembled into filomicelles that maintained ﬂexibility, but showed an 13 
increased filomicelle yield (93% vs 79%). The cell entry of PEG-PBCL filomicelles by A549 cells 14 
increased with first-order kinetics (time constant of 85 h) compared to a parabolic curve of PEG-PCL 15 
filomicelles.[73] PEG-PCL filomicelles had higher accumulation initially but were surpassed by PEG-16 
PBCL on day 3, suggesting that the cell uptake was dominant in the cell delivery compared to the drug 17 
release, for which the PEG-PBCL system was slower. Antibody coupled nanorods showed higher 18 
adhesion propensity than spherical particles that carried the same antibody and several folds higher 19 
adhesion than the nonspecific antibody coupled nanorods in static conditions and under flow.[66] The 20 
above results suggest the necessity to evaluate the contribution of shape towards internalization in the 21 
context of surface chemistry, material stiffness and concentration.[45,69,74–77]  22 
4.2 Cellular internalization of shaped polymersomes 23 
Compared to wormlike micelles, tubular nanoparticles can encapsulate and deliver water-24 
soluble substances within their lumen and hydrophobic molecules within their membrane.[18,78] As a 25 
typical tubular morphology, carbon nanotubes are held together by strong covalent bonds, which 26 
makes them stiff and inflexible, and their entry into cells occurs through a “needle-like” penetration of 27 
the membrane.[79,80] They were cleared from the body within hours after intravenous injection.[81] Only 28 
recently, soft polymeric tubular polymersomes were devised based on a variety of methods. However, 29 
there have only been very limited reports on the internalization of polymersome tubes. Battaglia et al 30 
reported the effects of polymersome shape on internalization kinetics of pH-sensitive poly(2-31 
(methacryloyloxy)ethyl phosphorylcholine)-poly(2-(diisopropylamino)ethyl methacrylate) (PMPC-32 
PDPA) tubular polymersomes.[82] The spherical polymersomes were previously applied as carriers for 33 
drugs and DNA delivery.[83,84] Kinetic studies revealed a biphasic uptake profile of tubular 34 
polymersomes by neutrophils, corresponding to an initial quick binding step before 9 h followed by a 35 
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slow internalization after 9 h (Figure 9). In comparison, the spherical polymersomes showed a rapid 1 
internalization followed by a single plateau.[82] Despite the unfavorable tube length for endocytosis, 2 
the tubes displayed high cellular uptake. This was ascribed to the multiple binding sites of PMPC for 3 
its receptors, leading to local destabilization and deformation of the plasma membrane, and 4 
progression to full endocytosis with the assistance of components of the cytoskeleton and other 5 
molecular endocytic players. The quick internalization rate, higher drug loading and similar uptake 6 
number of these tubes compared to spherical ones highlight their higher drug delivery capacity. These 7 
tubes loaded with drugs displayed increased cellular ATP levels of parkin mutant fibroblasts, thus 8 
rescuing mitochondrial function without any apparent cytotoxicity.[85]  9 
 10 
Figure 9. Internalization of tubular polymersomes. (A) The uptake rate of rhodamine-conjugated 11 
tubular polymersomes in neutrophils measured by flow cytometry. (B) Binding and internalization of 12 
tubular polymersomes in neutrophils visualized by confocal microscopy at 5 and 9 h. Scale bar 13 
represents 5 μm. Reprinted with permission.[82] 14 
Huang et al investigated the interaction between the tubes and the cell membrane using a 15 
Dissipative Particle Dynamics (DPD) simulation method.[86] Three different interaction pathways were 16 
identified: membrane wrapping, tube-membrane fusion and tube pearling, depending on the tube-cell 17 
membrane adhesion strength and membrane surface tension. A strong tube-cell membrane adhesion 18 
induced significant membrane wrapping. Soft tubes can be wrapped from the top by membranes via 19 
membrane monolayer protrusion, which together with tube deformation cooperatively makes the 20 
wrapping dynamics heterogeneous along the axial direction. A weak tube-cell membrane adhesion 21 
promoted tube pearling. The tubes can sometimes fuse with cell membranes under highly positive 22 
membrane tension, and molecules diffuse from tubes to membranes, which leads to the increase of 23 
tube tension and promotes tube pearling.  24 
4.3. Influence of shape on cytotoxicity 25 
Cytotoxicity is the direct and cooperative result of the internalization and drug release from 26 
the shaped particles. The cylindrical nanoparticles have a large volume for drug loading and multiple 27 
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and strong binding to the cell membrane and are expected to lead to highly efficient killing of target 1 
cells. The loading capacity, retention, and release of the drugs are important factors. Generally, drug 2 
loading capacity of filomicelles depends on the interaction between drug molecules and the 3 
copolymers.[73,87,88] The filomicelles of PEO-PCL (5-6.5 kDa) could load paclitaxel (PTX) of 4 
approximately 2.8 wt.%, twice as much as their spherical micelles. In vitro PTX release rates from 5 
both morphologies were similar, and were faster at pH 6.8 (mimicking the slightly acidic cancerous 6 
tissue environment) than at pH 7.4 (normal tissue pH). These results are contradictory to a previous 7 
report that shows a higher release rate from rod than spheres.[89] The PEG-PBCL filomicelles showed 8 
enhanced PTX loading by 40% and decreased PTX leakage compared to PEO-PCL filomicelles.[73] 9 
MTT assay results indicated that PTX-loaded PEG-PBD and PEG-PCL filomicelles showed 5-fold 10 
greater anticancer activity against A549 human lung cancer cells than that of free PTX.[33]. PTX-11 
loaded PEG-PBCL filomicelles further increased cytotoxicity 2.5-times compared to PEG-PCL 12 
filomicelles, and resulted in the greatest aneuploidy among surviving cells compared with PEG-PCL 13 
filomicelles and free PTX. The increased hydrophobicity of PBCL improved the PEG-PBCL 14 
filomicelle cellular uptake compared to PEG-PCL, despite of the slower drug release kinetics. It is 15 
noted that the empty filomicelles of PEG-PCL and PEG-PBCL were far less toxic than the clinically 16 
used Cremophor/EL in TAXOL.[73,90] The IC50 of DOX-loaded folate-targeted cylindrical micelles 17 
based on cyclodextrin was half of the nontargeted micelles and free DOX using KG-1 (folate positive 18 
receptor) cell lines, illustrating that targeting ligands can further enhance the cell internalization and 19 
cytotoxicity of cylindrical nanoparticles.[87] 20 
5. Effect of shape on the performances of nanoparticles in vivo 21 
Considering the great potential of cylindrical particles as drug carrier, in vivo evaluations of 22 
shaped particles with regard to blood circulation, biodistribution and tumor inhibition were 23 
conducted.[66,67,71,73,91] To prevent premature drug release caused by insufficient in vivo stability and 24 
low drug efficacy owing to low intracellular drug concentration that polymeric nanomedicines 25 
normally encounter,[92,93] chemical crosslinking, tumor specific targeting as well as stimulus-sensitive 26 
cylindrical nanoparticles were developed.[66,68,91,94] The promising application of cylindrical 27 
nanoparticles in drug delivery systems was thus demonstrated. 28 
5.1. Circulation time  29 
Discher’s pioneering work [67,90] demonstrated that the soft PEO-PCL filomicelles could 30 
circulate up to one week after intravenous injection in rats, which was about ten times longer than any 31 
known synthetic spherical nanoparticles. Biodegradable rod-like micelles (40 nm in diameter and 600 32 
nm in length) possess a minimal uptake by the RES and a longer blood circulation half-life (t1/2β = 33 
24.23 h) than that of spheres (t1/2β = 8.39 h) in mice.[95] Generally, spherical nanovehicles can enter 34 
cells and circulate in vivo for a few hours, while spherical microparticles are cleared instantly in the 35 
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microvasculature of organs and do not enter most cells. Notably, the flexibility of PEG-PCL micelles 1 
are about ten times lower than PEG-PBD micelles; however, they both could circulate for more than a 2 
week, indicating that the flexibility of filomicelles was important but weak in its effects in vivo.[67] 3 
Nevertheless, the circulation time was dependent on the length of filomicelles, and PTX loaded 4 
filomicelles with length of approximately 8 µm had the longest circulation time compared to spheres 5 
and other filomicelles (Figure 8D).[67] Since clinical studies have demonstrated that circulation times 6 
of spherical carriers are generally extended threefold in humans over rats,[96] the circulation time for 7 
filomorphologies could approach one month in humans. Such long circulation times may offer high 8 
drug efficacy against cancer cells by favoring drug accumulation through the leaky vasculature of 9 
solid tumors [77,97,98] and reduce off-target effects.[99] 10 
5.2. Biodistribution 11 
The MPS system of the liver and spleen is responsible for filtration and clearance of 12 
circulating particulates and some filamentous viruses. The biodistribution study of PEG-PCL 13 
filomicelles in rat organs showed that the liver and, to a lesser extent, the spleen dominate the (slow) 14 
clearance of filomicelles.[67] They had measurable accumulation in the kidney, owing to hydrolytic 15 
degradation products that might permeate the fine mesh of the kidneys. Moreover, the PEG-PCL 16 
filomicelle had moderate buildup in the lung, which was consistent with the minimal lung 17 
accumulation of poly(2-ethyl-2-oxazoline)-PCL-based filomicelles in rat.[70] Coupling antibodies 18 
changed the biodistribution of the cylindrical nanoparticles in vivo. In healthy mice, specific 19 
cylindrical nanoparticles, surface-modified with anti-intracellular adhesion molecule 1 or 20 
antitransferrin receptor antibodies, exhibited much higher lung or brain tissue accumulation, 21 
respectively, than spheres with the same surface chemistry and IgG-coated cylindrical 22 
nanoparticles.[66] Stenzel et al studied cylindrical micelles’ biodistribution in mice as a function of 23 
crosslinking and folate conjugation of micelles, which were based on a block copolymer of 24 
polyethylene glycol methyl ether acrylate and oxoplatin conjugated acrylic acid.[91] The crosslinked 25 
micelles displayed an increased drug accumulation in the organs compared to noncrosslinked ones. 26 
The targeting worm micelles had 3- or 7-fold higher accumulation in organs (especially spleen, liver 27 
and kidneys) than spherical micelles with or without folate, respectively. The long residence time on 28 
the cell surface before internalization for cylindrical particles[82] and the polyvalent interactions 29 
between targeting ligands and receptors on the cell surface[66] contribute significantly to tumor 30 
accumulation and penetration. 31 
5.3 In vivo antitumor efficacy 32 
The first antitumor study of filomorphologies was done using PTX-loaded PEG-PCL 33 
filomicelles of 1 µm or 8 µm in length. At a dosage of 1 or 8 mg PTX/kg, the filomicelles were 34 
injected i.v. into A549 tumor xenografts in nude mice. The 8 µm filomicelles, having the longest 35 
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circulation time, demonstrated the greatest tumor shrinkage in mice compared to spheres and other 1 
filomicelles due to the effective delivery of PTX into tumor cells. Notably, 8 µm long filomicelles at 1 2 
mg PTX/kg brought about the same therapeutic effects as 1 µm long filomicelles at 8 mg PTX/kg 3 
(Figure 1E).[67] Both increase in micelle length or PTX content resulted in a doubling of apoptosis of 4 
cancer cells in the tumor and a similar extent of decrease in tumor size. Apparently, the circulation 5 
time and drug loading content as well as concentration of filomicelles in vivo all affect their final 6 
therapeutic performance, providing a clear indication to lung tumors. Preliminary in vivo antitumor 7 
experiments in nude mice bearing A549 xenografts showed that PTX-loaded PEG-PBCL filomicelles 8 
produced 25% tumor shrinkage in 2 weeks at one-fourth PTX dosage of PTX-loaded PEG-PCL 9 
filomicelles.[73] The high potency of PTX-loaded PEG-PBCL filomicelles towards the same tumor 10 
indicates that simple chemical variation may contribute to high antitumor efficacy. The high aspect 11 
ratio in rod-shape nanoparticles affects their interaction with cancer cells and has a great potential to 12 
promote their tumor penetration depth, which innovates the approach in nanomedicine design. For 13 
instance, compared with nanospheres with the same hydrodynamic diameter, quantum dot-based 14 
nanorods displayed enhanced penetration in orthotopic mammary tumors at 1 h postinjection in 15 
mice.[13] Additionally, single-walled carbon nanotubes displayed enhanced tumor penetration 16 
compared with spherical quantum dots in U87MG tumor models.[100] The activatable porphyrin 17 
nanodiscs (10 to 30 nm) in an in vitro model showed 5-fold enhanced diffusive properties in a 18 
collagen-rich environment, demonstrating the potential improvement in penetration in dense solid 19 
tumors. [101] 20 
Stimulus-responsive cylindrical nanoparticles can facilitate the site-specific destabilization and 21 
fast drug release in the diseased sites in response to special cues in the tumor environment, providing 22 
benefits for further accumulation inside tumor cells. For instance, tumor tissue pH responsive worm 23 
micelles (PHWMs) loaded with photosensitizing drug chlorin e6 (Ce6)[94] displayed higher cellular 24 
uptake, increased singlet oxygen generation and improved photoactivity when KB cells were treated at 25 
pH 6.8–6.0 upon light illumination compared to pH 7.4. Moreover, treatment of KB tumor bearing 26 
nude mice with a single dose of Ce6-loaded PHWMs showed more accumulation at the tumor site than 27 
nonsensitive micelles or free Ce6, leading to 5.2 time higher tumor growth inhibition than those 28 
treated with free Ce6.  29 
 30 
6. Conclusion 31 
The past decade has witnessed increasing interest in the development of morphologically 32 
discrete nanoparticles, in particular polymersomes and micelles, as advanced carriers for anticancer 33 
nanomedicines. The novel fabrication methods developed by different research groups make it 34 
possible to prepare sophisticated polymersomes and micelles with varying morphologies ranging from 35 
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wormlike micelles and tubes to discs and stomatocytes. It is interesting to note that shaped 1 
nanoparticles and nanomedicines show distinct behaviors from spherical ones in vitro and in vivo, 2 
which signifies the important role of vehicle morphology in cancer therapy. Gaining control over 3 
particle morphology is an ever-increasing field of research that will hold a solid future in 4 
nanomedicine applications. However, there remain many pitfalls to be overcome or be taken into 5 
consideration on conducting follow-up research or translating this knowledge into clinical trials. One 6 
of the pitfalls of designing different morphologies for drug delivery platforms is that although our 7 
knowledge of the effect of morphology in vivo and in vitro is ever increasing, cell interactions and in 8 
vivo processes such as opsonization can remain extremely shape or size specific. This indicates that 9 
utilizing the morphology, size or shape of drug delivery platforms might increase the specificity but 10 
decrease general applicability.  11 
In spite of significant progress, fabrication of polymersomes and micelles with shaped 12 
morphologies remains empirical. So far, wormlike micelles, tubes, discs and stomatocytes can be 13 
prepared only from certain copolymer at a narrow composition range and under particular conditions. 14 
In most cases, employed polymers are not biodegradable or biocompatible, which renders previously 15 
reported shaped nanoparticles with little potential for clinical translation, although they can be 16 
interesting as a model to study the effect of shape on drug delivery in vitro and in vivo. The dimension 17 
of wormlike micelles, tubes, discs and stomatocytes is another concern since many of them are long 18 
(from hundreds to thousands of nanometers) or too large. It would be more interesting if there is a 19 
robust method to fabricate short wormlike micelles and tubes or small-sized discs and stomatocytes 20 
based on well-accepted biodegradable and biocompatible materials such as polylactide and poly(ε-21 
caprolactone). Given the fact that most shaped nanoparticles are only used as a model system, which is 22 
not optimal for cancer therapy in terms of materials and/or dimension, so far there is no report on 23 
biosafety studies for shaped polymeric nanosystems, which is vital for clinical applications. Moreover, 24 
most of the shaped nanoparticles have no active targeting ligands. However, to achieve selective 25 
uptake by target tumor cells and precision cancer chemotherapy, active targeting is of critical 26 
importance. Last but not least, most shaped nanoparticles reveal low drug loading efficacy and 27 
sustained release profile. For clinical translation, drug encapsulation in shaped nanoparticles has to be 28 
improved. Furthermore, to potentiate their antitumor efficacy, tumor microenvironment-sensitive 29 
nanoparticles that trigger drug release at the target site are desired. In conclusion, there remain many 30 
scientific challenges for shaped nanomedicines in cancer therapy ranging from design, fabrication and 31 
characterization to in vitro and in vivo validation. 32 
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